ALBANY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wi......
Monterrey 1 new Advanced Lighthouse and Shanghai new End-to-End Value Chain Lighthouse, the company now has seven factories that have achieved Lighthouse statusThese are leading examples of how Fourth......
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women
TVB-009P, Teva’s proposed biosimilar to Prolia, ......
ORBCOMM partners with industry stakeholders to accelerate climate action and reduce greenhouse gas emissions, energy consumption and supply chain costs
Commercial 5G Standalone
Enabling secure tailored end-to-end communications
Dedicated slices to meet specific needs of the Armed Forces
Extending strategic partnership with key customer
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on ......
